Presentation is loading. Please wait.

Presentation is loading. Please wait.

Diffusion Physics H 2 O in the body is always in random motion due to thermal agitation B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen.

Published byBaldric Green Modified over 8 years ago

Similar presentations

Presentation on theme: "Diffusion Physics H 2 O in the body is always in random motion due to thermal agitation B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen."— Presentation transcript:

1

2 Diffusion Physics H 2 O in the body is always in random motion due to thermal agitation B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010

3 Detecting Diffusion with MRI - Intravoxel Incoherent Motion Ellingson et al., Concepts in MR, 2008 B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010 From: Ellingson, Concepts in MR, 2008

4 Detecting Diffusion with MRI - Intravoxel Incoherent Motion Detected DWI Signal MRI Signal w/o Diffusion Sensitivity Variability in Phase of “Tagged” H 2 O Level of Diffusion Weighting Diffusion Coefficient B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010

5 Proton on H 2 O Image Voxel  = t 1  = t 2  = t 3 MRI Signal Diffusion Time (or level of diffusion weighting) B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010

6 Apparent diffusion coefficient (ADC) measured clinically reflects extracellular water ADC is dependent on tumor cell density (Ellingson, 2010; Sugahara, 1999; Lyng, 2000; Chenevert, 2000; Gaurain, 2001; Nonomura, 2001; Guo, 2002; Chen, 2005; Hayashida, 2006; Manenti, 2008; Kinoshita, 2008 –  Cell Density (hypercellular) =  ADC –  Cell Density (hypocellular) =  ADC Diffusion MR Characteristics of the Central Nervous System Viable Tumor (Dark) Necrotic Core Edema ADC Map From: Ellingson, J Magn Reson Imaging, 2010 B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010

7 Diffusion MRI During Successful Cytotoxic Therapy From: Ross, Mol Cancer Ther, 2003 B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010

8 The Functional Diffusion Map (fDM) (Moffat, 2005; 2006; Hamstra, 2005; 2008; Ellingson, 2010) From: Ellingson, JMRI, 2010 B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010

9 Early Detection of Brain Tumor Growth T1+C FLAIR fDMs Hypercellular Regions (Blue) Contrast-Enhancement (white) B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010

10 fDMs in Brain Tumor Progression T1+C FLAIR fDM 3 mo.6 mo.9 mo. (Onset of symptoms) B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010

11 From: Ellingson, ISMRM, 2009; SNO, 2009 B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010 fDMs in Progressive Disease (PD)  Hypercellularity

12 Positive Tumor Response to Treatment Day 89 Day 180Day 237Day 298 Hypercellular Tumor Hypocellular “Treated” Tumor B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010 From: Ellingson, ISMRM, 2009; SNO, 2009

13 B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010 fDM Results in Stable/Responding Disease (SD/RD)  Hypocellularity

14 From: Ellingson, ISMRM, 2009; SNO, 2009 B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010 fDMs May Reflect Molecular/Genetic Phenotypes MGMT(+) MGMT(-)

15 (n = 50 Total Patients) Spearman Corr. Coeff. R = 0.4350, P = 0.0016 Clinical fDM Sensitivity/Specificity WHO Grade B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010From: Ellingson BM et al., ISMRM, 2010

16 (n = 50 Total Patients) Pearson Corr. Coeff. R 2 = 0.8586, P < 0.0001 Clinical fDM Sensitivity/Specificity Neurological Status B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010From: Ellingson BM et al., ISMRM, 2010

17 fDMs as an early biomarker for cytotoxic and new anti-angiogenic treatments From: Ellingson BM, J Neuroonc, 2010 B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010

18 Volumetric Analysis of fDMs as an early biomarker for cytotoxic and new anti-angiogenic treatments From: Ellingson BM, J Neuroonc, 2010 fDMs detect PD > 2 months before recurrence BevacizumabTemozolomide fDMs predict survival and progression better than age and tumor grade! B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010

19 Better Defining  ADC Thresholds for Classification From: Ellingson, JMRI, 2010  ADC = 95% C.I. NAWM  ADC = 95% C.I. NAGM  ADC = 95% C.I. NAWM+NAGM  ADC = 95% C.I. NAWM+NAGM+CSF Different  ADC thresholds reflect different sensitivity/specificity to growing tumor B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010

20 Better Defining  ADC Thresholds for Classification From: Ellingson, JMRI, 2010 Different  ADC thresholds reflect different sensitivity/specificity to growing tumor B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010

21 Graded fDMs Allow Visualization and Quantification of Growing Tumor + Hypercellular+ Hypocellular B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010 Biological Calibration From: Ellingson, JMRI, 2010

22 Graded fDMs Allow Better Visualization of Growing Tumor + Hypercellular+ Hypocellular B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010

23 Graded fDMs Allow Better Visualization of Growing Tumor B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010

24 Hypercellular Hypocellular Macrophages & Inflammatory Cells Demyelination Graded fDMs in Differential Diagnosis Tumor vs. Demyelination Biopsy Diagnosis = Demyelination (Multiple Sclerosis) B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010

25 Graded fDMs can distinguish radiation necrosis from tumor Hypercellular Hypocellular T1+C FLAIR Graded fDM B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010

26 Diffusivity Mismatch Index (DMI) predicts survival B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010 From: Ellingson, Clin Cancer Res, 2010, Submitted

27 Diffusivity Mismatch Index (DMI) predicts survival B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010 From: Ellingson, Clin Cancer Res, 2010, Submitted

28 Cell Invasion, Migration, and Proliferation Level Estimates = CIMPLE Maps Higher-order changes in ADC over time and space Allows us to map estimates of invasion and proliferation B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010 From: Ellingson, Magn Reson Med, 2010, Accepted

29 B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010 Whole Brain CIMPLE Maps & 18 F-FDOPA PET From: Ellingson, Magn Reson Med, 2010, Accepted

30 B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010 Whole Brain CIMPLE Maps & 18 F-FDOPA PET -10 Cell Proliferation [1/yr] 10

31 CIMPLE Maps Pre-Tx Post-Tx  Recurrence B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010 From: Ellingson, Cancer Imaging, 2010, Submitted

32 CIMPLE Maps (Doubling Times) Doubling Time Days 3650 Within physiologic range of doubling times: 22 days (GBM) - 556 days (WHO II) Blankenberg et al, AJNR, 2005 B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010

33 CIMPLE Maps (Doubling Times) Doubling Time Days 3650 B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010 Doubling Time (Days) 50< 10403020

34 B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010 Mean proliferation at start of treatment predicts survival (defined from time of CIMPLE map) N = 26 From: Ellingson, Cancer Imaging, 2010, Submitted

35 Conclusions Diffusion MRI is sensitive to cell density Functional diffusion maps (fDMs) reflect voxel- by-voxel changes in cellularity fDM kinetics are useful for individual patient monitoring B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010

36 Graded fDMs allow for degree of cellularity to be visualized and quantified (biological basis) Graded fDMs can distinguish radiation necrosis from tumor recurrence CIMPLE maps allow visualization and quantification of invasion and proliferation rates Conclusions B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010

37 Radiology Whitney Pope, M.D., Ph.D. Dieter Enzmann, M.D. Jonathan Goldin, M.D. MedQIA Neurology/Neuro-Oncology Timothy Cloughesy, M.D. Albert Lai, M.D., Ph.D. Neurosurgery Linda Liau, M.D. Bob Shafa, M.D. Antonio DeSalles, M.D. Pathology Paul Mischel, M.D. Bill Yong, M.D. Thank You! B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2010 Radiology Kathleen Schmainda, Ph.D. Scott Rand, M.D., Ph.D. Neurology/Neuro-Oncology Mark Malkin, M.D. Jennifer Connelly, M.D. Neurosurgery Wade Mueller, M.D. Shekar Kurpad, M.D., Ph.D.

Download ppt "Diffusion Physics H 2 O in the body is always in random motion due to thermal agitation B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen."

Similar presentations

Neuroradiology Natasha Wehrli, MS4 University of Pennsylvania School of Medicine.

Neuroradiology Natasha Wehrli, MS4 University of Pennsylvania School of Medicine.
A phase I dose escalating study of intensity modulated radiation therapy (IMRT) for the treatment of glioblastoma multiforme (GBM) ( #1008) V. Stieber.

A phase I dose escalating study of intensity modulated radiation therapy (IMRT) for the treatment of glioblastoma multiforme (GBM) ( #1008) V. Stieber.
Neuroradiology Dr Mohamed El Safwany, MD. Intended Learning Outcomes  The student should be able to understand role of medical imaging in the evaluation.

Neuroradiology Dr Mohamed El Safwany, MD. Intended Learning Outcomes  The student should be able to understand role of medical imaging in the evaluation.
Mapping Cortical Development Using Diffusion Tensor Imaging Jeff Neil, MD, PhD Departments of Neurology, Radiology and Pediatrics.

Mapping Cortical Development Using Diffusion Tensor Imaging Jeff Neil, MD, PhD Departments of Neurology, Radiology and Pediatrics.
Diffusion Physics - Thermal Agitation - In steady state, the motion of water is dominated by thermal agitation. -This causes “random” motion of water.

Diffusion Physics - Thermal Agitation - In steady state, the motion of water is dominated by thermal agitation. -This causes “random” motion of water.
Differential Diagnosis of Bright Lesions on Diffusion-weighted MR Images Fahad albadr MD.

Differential Diagnosis of Bright Lesions on Diffusion-weighted MR Images Fahad albadr MD.
B.M. Ellingson 1,2, M.G. Malkin 1,3,4, S.D. Rand 1,2, J.M. Connelly 3, C. Quinsey 4 P.S. LaViolette 1,5, D.P. Bedekar 1,2, and K.M. Schmainda 1,2,5 B.M.

B.M. Ellingson 1,2, M.G. Malkin 1,3,4, S.D. Rand 1,2, J.M. Connelly 3, C. Quinsey 4 P.S. LaViolette 1,5, D.P. Bedekar 1,2, and K.M. Schmainda 1,2,5 B.M.
ABSTRACT ID NO: IRIA - 1085 ROLE OF DIFFUSION WEIGHTED IMAGING IN UTERINE AND CERVICAL LESIONS.

ABSTRACT ID NO: IRIA ROLE OF DIFFUSION WEIGHTED IMAGING IN UTERINE AND CERVICAL LESIONS.
ACRIN Breast Committee Fall Meeting 2010 6657 Extension-CONTRAST-ENHANCED BREAST MRI and MRS FOR EVALUATION OF PATIENTS UNDERGOING NEOADJUVANT TREATMENT.

ACRIN Breast Committee Fall Meeting Extension-CONTRAST-ENHANCED BREAST MRI and MRS FOR EVALUATION OF PATIENTS UNDERGOING NEOADJUVANT TREATMENT.
In biochemical recurrence after curative treatment of prostate cancer, Choline PET/CT 1- has a detection rate of 10-20% when PSA: 1-2 ng/ml 2- has a detection.

In biochemical recurrence after curative treatment of prostate cancer, Choline PET/CT 1- has a detection rate of 10-20% when PSA: 1-2 ng/ml 2- has a detection.
The Dependence of the Apparent Diffusion Coefficient on Voxel Location and Calculation Method Lars Ewell 1, Naren Vijayakumar 2 2007 Meeting of the American.

The Dependence of the Apparent Diffusion Coefficient on Voxel Location and Calculation Method Lars Ewell 1, Naren Vijayakumar Meeting of the American.
Functional Diffusion Maps (fDMs) for Brain Tumor Treatment Response Monitoring Benjamin M. Ellingson, Ph.D. Assistant Professor of Radiology Dept. of Radiological.

Functional Diffusion Maps (fDMs) for Brain Tumor Treatment Response Monitoring Benjamin M. Ellingson, Ph.D. Assistant Professor of Radiology Dept. of Radiological.
Diffusion Physics H 2 O in the body is always in random motion due to thermal agitation B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen.

Diffusion Physics H 2 O in the body is always in random motion due to thermal agitation B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen.
Original Article B-Cell Depletion with Rituximab in Relapsing- Remitting Multiple Sclerosis Stephen L. Hauser, M.D., Emmanuelle Waubant, M.D., Ph.D., Douglas.

Original Article B-Cell Depletion with Rituximab in Relapsing- Remitting Multiple Sclerosis Stephen L. Hauser, M.D., Emmanuelle Waubant, M.D., Ph.D., Douglas.
Diffusion MRI is sensitive to brain tumor cell density Clinical ADC and cell density are negatively correlated (Sugahara, 1999; Lyng, 2000; Chenevert,

Diffusion MRI is sensitive to brain tumor cell density Clinical ADC and cell density are negatively correlated (Sugahara, 1999; Lyng, 2000; Chenevert,
Pre-Tx 18 F-FDOPA PET Pre-Tx T1+C Post-Tx 18 F-FDOPA PET Difference Post-Pre Tx 18 F-FDOPA PET IOIS: 3401 Benjamin M. Ellingson, Ph.D., Dept. of Radiological.

Pre-Tx 18 F-FDOPA PET Pre-Tx T1+C Post-Tx 18 F-FDOPA PET Difference Post-Pre Tx 18 F-FDOPA PET IOIS: 3401 Benjamin M. Ellingson, Ph.D., Dept. of Radiological.
DegenerationRegeneration Traumatic Injury Degenerative Disease Radiation/Chemotherapy Brain Tumors Stem Cells & Regenerative Medicine B.M. Ellingson, Ph.D.,

DegenerationRegeneration Traumatic Injury Degenerative Disease Radiation/Chemotherapy Brain Tumors Stem Cells & Regenerative Medicine B.M. Ellingson, Ph.D.,
Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR.

Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR.
Taylor J Greenwood, MD, Adam Wallace, MD, Aseem Sharma, MD, Jack Jennings, MD, PhD.

Taylor J Greenwood, MD, Adam Wallace, MD, Aseem Sharma, MD, Jack Jennings, MD, PhD.
Radiation Injury Can Mimic Tumor Progression Following Proton Radiotherapy for Atypical Teratoid Rhabdoid Tumor in Pediatric Patients M Chang 1, F Perez.

Radiation Injury Can Mimic Tumor Progression Following Proton Radiotherapy for Atypical Teratoid Rhabdoid Tumor in Pediatric Patients M Chang 1, F Perez.

Similar presentations

Ads by Google